Erdosteine

Erdosteine is a new expectorant introduced in France for the treatment of chronic bronchitis. Erdosteine possesses mucomodulator, mucolytic, mucokinetic and free radical scavenging properties. Its therapeutic efficacy has been demonstrated in patients affected by congestion and viscous mucus in higher and lower respiratory tracts as in acute and chronic bronchitis, sinusitis, otitis, tracheopharyngitis and coryza. Erdosteine acts through its active metabolites containing free sulfhydryl groups which are able to depolymerize the mucopolysaccharides of the excreatum by breaking the disulfide linkages (thereby lowing its viscosity). The prodrug approach provides unique characteristics to erdosteine by offering stable therapeutic efficacy and prevention of the gastric mucus from lythic phenomena. The agent was also reported to have local antiinflammatory and antielastase properties and enhances penetration of antibiotics into bronchial mucus.

Erdosteine is a mucolytic agent and an antioxidant. It inhibits LPS-induced IκB kinase (IKK) activity, NF-κB-mediated transcription, and production of IL-6 and IL-1β in RAW 264.7 cells. Erdosteine (7.5 mg/kg) prevents depletion of renal catalase and glutathione peroxidase (GPX) and increases in renal malondialdehyde (MDA) and nitric oxide (NO) levels in a rat model of nephrotoxicity induced by cisplatin . It reduces spinal cord lipid peroxidation and destruction of spinal motor neurons in a rabbit model of spinal cord ischemia and reperfusion injury induced by thoracoabdominal aortic clamping. Erdosteine (150 mg/kg) reduces lung weight, MDA and protein carbonyl levels, and macrophage and neutrophil accumulation in a mouse model of acute lung injury induced by oleic acid (Item Nos. 90260 | 24659). Formulations containing erdosteine have been used in the treatment of chronic obstructive pulmonary disease (COPD).

Off-White Solid

Refarmed (Switzerland)

Erdosteine is a mucolytic. Erdosteine was developed for the treatment of chronic obstructive bronchitis.

A mucolytic, developed for the treatment of chronic obstructive bronchitis.

ChEBI: Erdosteine is a N-acyl-amino acid.

Edirel; Vectrine

[1] JONG SUN PARK. Anti-inflammatory Effect of Erdosteine in Lipopolysaccharide-Stimulated RAW 264.7 Cells.[J]. Inflammation, 2016, 39 4: 1573-1581. DOI: 10.1007/s10753-016-0393-4
[2] MAURIZIO MORETTI  Carlo F M. An overview of erdosteine antioxidant activity in experimental research[J]. Pharmacological research, 2007, 55 4: Pages 249-254. DOI: 10.1016/j.phrs.2006.12.006
[3] AYEN ERDEM MD , PHD  Meltem T M  Ersin Fadillioglu MD. Protective role of erdosteine pretreatment on oleic acid–induced acute lung injury[J]. Journal of Surgical Research, 2017, 213: Pages 234-242. DOI: 10.1016/j.jss.2017.02.061